



(410) 424-4037

## **USFHP Pharmacy Prior Authorization Form**

JOHNS HOPKINS	To be completed by Requesting provider	
HEALTHCARE	Drug Name:	Strength:
7231 Parkway Drive, Suite 100, Hanover, MD 21076		5
FAX Completed Form and	Dosage/Frequency (SIG):	Duration of Therapy:
<b>Applicable Progress Notes to:</b>		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):				
1	Patient Name:	Name: Physician Name:			
	Address:	Address:			
	· · · · · · · · · · · · · · · · · · ·	DI //			
	Sponsor ID # Date of Birth:	Phone #: Secure Fax #:			
Step		Secure Fax #:			
'	Please complete the clinical assessment:				
2	1. Is the patient greater than or equal to 18 years of ag	e? 🗆 Yes	□ No		
		Proceed to ques	stion 2 STOP		
			Coverage not approved		
	2. Does the patient have unresectable or metastatic melanoma?	□ Yes	🗆 No		
	melanoma ?	Proceed to ques	stion <b>3</b> Proceed to question <b>7</b>		
	3. Does the patient have BRAF V600E or BRA FV600K mutation confirmed by an FDA-approved test?	□ Yes	□ No		
		Proceed to ques	stion 4 Proceed to question 7		
	4. Will Mektovi be taken in combination with Braftovi?	□ Yes	🗆 No		
		Proceed to ques	stion <b>5</b> Proceed to question <b>7</b>		
	5. Is the patient on dabrafenib (Tafinlar), trametinib (Mekinist), vemurafenib (Zelboraf), or cobimetinib	□ Yes	🗆 No		
	(Cotellic) concurrently?	STOP	Proceed to question 6		
		Coverage not ap	proved		
	6. Is the requested medication being prescribed by or	in 🗆 Yes	□ No		
	consultation with an oncologist?	Sign and date	below STOP		
			Coverage not approved		

Proceed to	question 8
☐ Yes Sign and date below	□ No STOP
	Coverage not approved
	□ Yes

## .

3

Date

[14 August 2019]

For Internal Use Only	
Approved:	Duration of Approval:month(s)
Denied:	Authorized By:
Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: